Resumen de: AU2020202974A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

Resumen de: US2020155617A1

This application provides for methods of treatment for IBD, especially in subjects who have R. gnavus species or R. gnavus group IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.

Resumen de: US2020149087A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

Resumen de: US2020149110A1

This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

Resumen de: AU2018349287A1

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

Resumen de: AU2018304283A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

Resumen de: WO2020087130A1

Provided herein are methods and kits for determining a prognosis and/or treatment of a subject with IBD. Methods and kits for assessing susceptibility to and/or determining the presence and/or treatment of dysbiosis in a subject are also described herein.

Resumen de: US2020141949A1

Disclosed is a method that uses Rho GDP dissociation inhibitory 2 protein as a diagnostic and prognostic marker of inflammatory bowel diseases by way of the ex vivo detection of the protein level in faecal samples of patients.

Resumen de: WO2018237064A1

A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohns disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohns disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohns disease.

Resumen de: WO2020081186A1

Described herein are methods of treatment of an inflammatory condition related to fungal immunity. The present disclosure relates to methods and systems for identifying patients suitable for treatment with active agents, as described herein. Further, described herein are various compositions for treating and identifying a subject in need of an active agent for treatment.

Resumen de: WO2020077397A1

The present invention relates to the treatment of mucosal lesions in the gastrointestinal tract. Specifically, methods and pharmaceutical compositions are provided for the treatment of a mucosal lesion associated with a disorder of the gastrointestinal tract. The methods comprise administering to a subject an effective amount of an agent which decreases expression and/or activity of Flightless I in the subject. Treatment of disorders such as inflammatory bowel disease (including ulcerative colitis and Crohn's disease), coeliac disease, peptic ulcer disease, and regional ileitis are contemplated. Methods and associated kits for diagnosing a disorder of the gastrointestinal tract or for assessing the progression of a disorder of the gastrointestinal tract in a subject are also provided.

Resumen de: US2020121740A1

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

Resumen de: WO2020082011A1

The present disclosure provides methods for assessing responsiveness or non- responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures.

Resumen de: EP3639841A1

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

Resumen de: US2020113930A1

Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography.

Resumen de: US2020100725A1

A health diagnostics system includes an interne-of-things (IoT) toilet device adapted to be mounted on or within a toilet bowl. The IoT toilet device comprises one or more sensors for collecting measurements of human excrement residing within the toilet bowl and also includes an excrement analysis module stored in memory and executable by a processor to infer a property of a human bowel movement based on the collected measurements, where the inferred property includes at least one of color, volume, mass, consistency, and frequency

Resumen de: WO2020061507A1

Methods and devices for assessment of microvascular dysfunction, such as microvascular obstruction (MVO) and other dysfunctional diseases of the microvasculature of many organs, including the heart. The present subject matter provides novel devices and methods to successfully diagnose, restore patency, open and preserve flow, and limit reperfusion injury in organs and cases with microvascular dysfunction. The present subject matter provides apparatus and method to detect, measure and treat microvascular dysfunction in real time during scenarios such as invasive angiographic/therapeutic procedures. Such procedures include therapy for organ systems including the heart (acute myocardial infarction - primary percutaneous coronary intervention (PPCI)), brain stroke (CVA), bowel ischemia/infarction, pulmonary emboli/infarction, critical limb ischemia/infarction, renal ischemia/infarction, and others. The present subject matter provides various systems including an infusion and sensing catheter, diagnostic agents, therapeutic agents, and a control console with specialized algorithms to diagnose and treat microvascular dysfunction, such as MVO, in real-time with real-time operator feedback for intervention al procedures.

Resumen de: WO2020058968A1

The present invention relates to methods and kits for the diagnosis of inflammatory bowel disease (IBD) by detecting the expression of one or more circadian clock gene, or by detecting the expression of proteins encoded by said circadian clock gene. The methods and kits of the invention are further useful in differentiating between IBD and inflammatory bowel syndrome (IBS), for differentiating between the remission or exacerbation states of IBD, and for grading the severity of IBD. In an embodiment, the one or more clock gene biomarker is selected from the group consisting of: Circadian Locomotor Output Cycles Kaput (CLOCK), Aryl hydrocarbon receptor nuclear translocator-like protein 1 (BMAL1), Cryptochrome 1 (CRY1), Cryptochrome 2 (CRY2), Period 1 (PERI), and Period 2 (PER2).

Resumen de: AU2018328120A1

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.

Resumen de: WO2020051460A1

Described herein are methods and compositions for diagnosing, preventing, treating, or ameliorating symptoms of immune disorders including inflammatory bowel disease (IBD), Crohn's Disease and/or ulcerative colitis.

Resumen de: WO2020043864A1

The present invention relates generally to the field of inflammatory bowel disease (IBD), and in particular ulcerative colitis (UC). The present invention provides methods for predicting clinical course of UC in a patient. By being able to predict the clinical course of UC, it is now possible to conclude on a therapeutic approach adapted to reflect the actual clinical picture of the patient at an early stage. Such a diagnostic test will create new knowledge of high clinical utility for the clinician, create a personalized therapy for the patient, improve the prognosis for the patient and reduce health costs for the society.

Resumen de: US2020064330A1

Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.

Resumen de: WO2020040631A1

The present invention relates to a system comprising compositions and methods for obtaining, stabilising and applying an ex vivo model of gastrointestinal microbiota for use, for example, in the simulation of digestive processes, wherein the inclusion of the stabilised microbiota allows the carrying out of a wide range of studies on populations of microorganisms from donors belonging to a group of interest, according to a characteristic or condition related to age, gender, genotype/phenotype, ethnicity or race, or geographical location, or in relation to a specific change in the state of health, for example, caused by pathogens, nutritional aspects, obesity, renal insufficiency, metabolic disorders, etc. The stabilised microbiota, according to the present invention, can also come from a particular individual, for use in simulations of digestive processes to test therapies related to the formation of metabolites and the impact that they can have on the intestinal microbiota, for example, in cases of inflammatory bowel disease.

Resumen de: WO2020041287A1

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

Resumen de: CN110838365A

The invention discloses an irritable bowel syndrome related flora marker which can be used for developing a disease risk assessment system. According to the invention, an optimal set of 17 irritable bowel syndrome related flora markers is obtained, and a kit constructed based on the optimal set is used for diagnosing irritable bowel syndrome and can achieve higher accuracy.